Correlation Between Monopar Therapeutics and Eupraxia Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Monopar Therapeutics and Eupraxia Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Monopar Therapeutics and Eupraxia Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Monopar Therapeutics and Eupraxia Pharmaceuticals, you can compare the effects of market volatilities on Monopar Therapeutics and Eupraxia Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Monopar Therapeutics with a short position of Eupraxia Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Monopar Therapeutics and Eupraxia Pharmaceuticals.
Diversification Opportunities for Monopar Therapeutics and Eupraxia Pharmaceuticals
-0.44 | Correlation Coefficient |
Very good diversification
The 3 months correlation between Monopar and Eupraxia is -0.44. Overlapping area represents the amount of risk that can be diversified away by holding Monopar Therapeutics and Eupraxia Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eupraxia Pharmaceuticals and Monopar Therapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Monopar Therapeutics are associated (or correlated) with Eupraxia Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eupraxia Pharmaceuticals has no effect on the direction of Monopar Therapeutics i.e., Monopar Therapeutics and Eupraxia Pharmaceuticals go up and down completely randomly.
Pair Corralation between Monopar Therapeutics and Eupraxia Pharmaceuticals
Given the investment horizon of 90 days Monopar Therapeutics is expected to generate 8.45 times more return on investment than Eupraxia Pharmaceuticals. However, Monopar Therapeutics is 8.45 times more volatile than Eupraxia Pharmaceuticals. It trades about 0.08 of its potential returns per unit of risk. Eupraxia Pharmaceuticals is currently generating about -0.03 per unit of risk. If you would invest 202.00 in Monopar Therapeutics on September 1, 2024 and sell it today you would earn a total of 2,051 from holding Monopar Therapeutics or generate 1015.35% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Very Weak |
| Accuracy | 54.28% |
| Values | Daily Returns |
Monopar Therapeutics vs. Eupraxia Pharmaceuticals
Performance |
| Timeline |
| Monopar Therapeutics |
| Eupraxia Pharmaceuticals |
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Monopar Therapeutics and Eupraxia Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Monopar Therapeutics and Eupraxia Pharmaceuticals
The main advantage of trading using opposite Monopar Therapeutics and Eupraxia Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Monopar Therapeutics position performs unexpectedly, Eupraxia Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eupraxia Pharmaceuticals will offset losses from the drop in Eupraxia Pharmaceuticals' long position.| Monopar Therapeutics vs. Tff Pharmaceuticals | Monopar Therapeutics vs. Eliem Therapeutics | Monopar Therapeutics vs. Inhibrx | Monopar Therapeutics vs. Enliven Therapeutics |
| Eupraxia Pharmaceuticals vs. Akeso, Inc | Eupraxia Pharmaceuticals vs. Ascletis Pharma | Eupraxia Pharmaceuticals vs. Avax Techs | Eupraxia Pharmaceuticals vs. Eliem Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Other Complementary Tools
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |